Good Day BIO Newsletter

The EPA greenlit a BIO member’s groundbreaking biopesticide that targets a “super pest”—without harming the honeybees. Plus, we look at how Genentech’s MS clinical trial brings lessons on MS and clinical trial diversity. (538 words, 2 minutes, 41 seconds)

Happy 2024! Today, we have news you might have missed over the holidays: 19 House Democrats oppose expanding the COVID IP waiver, the IRS issues new guidance on SAF tax credits, and BIO talks PBMs and drug prices. (557 words, 2 minutes, 47 seconds)

The U.N. Food and Agriculture Organization (FAO) released a roadmap to reach food security without increasing global temperatures—we have the details and BIO’s response, plus all of your holiday reading. (592 words, 2 minutes, 57 seconds) Good Day BIO will take a holiday break, returning on January 2. We hope you enjoy the season and look forward to seeing you in 2024!

The Supreme Court will hear a case that will determine whether courts can overrule FDA’s authority on drug approvals—here’s what’s happening. Plus, President Biden is expected to tout drug price controls today. (581 words, 2 minutes, 54 seconds)

COP28 concluded with a deal to phase out fossil fuels and address methane—presenting an important role for biotech. Plus, state biotech associations recently sent a letter urging passage of the ORPHAN Cures Act and a BIO VP was elected to the National Health Council Board. (554 words, 2 minutes, 46 seconds)

The good news: The House passed PBM reform legislation yesterday. The bad news: FTC M&A overreach is causing “lasting damage” to American life sciences innovation, experts write, with another blow for patients this week. (693 words, 3 minutes, 27 seconds)

The Food and Drug Administration (FDA) on Friday approved the first cell-based gene therapies for sickle cell disease (SCD), including the first treatment to utilize CRISPR. Plus, catch up on COP28 and the weekend’s focus on food. (566 words, 2 minutes, 49 seconds)

A new poll finds voters overwhelmingly support the ORPHAN Cures Act to amend the Inflation Reduction Act’s price controls. Plus, Bayer’s CEO explains why we need to get over fears about gene editing plants if we want to tackle climate change. (687 words, 3 minutes, 26 seconds)

The White House made a surprise announcement today about using Bayh-Dole march-in rights. A House committee advanced additional PBM reform bills, and a new poll shows that Americans support advancing biotech to address climate change. (526 words, 2 minutes, 37 seconds)

It’s not too early to start thinking about your 2024 networking and business development opportunities—learn more about BIO’s JPM Events Guide app and an opportunity for early-stage startups to get support. Plus, BIO recently urged the President’s Export Council (PEC) to take action on agricultural exports. (544 words, 2 minutes, 43 seconds)